Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06585241 · ClinicalTrials.gov registry record · Phase 4
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
A Phase 4 study of SARS-CoV-2, sponsored by ModernaTX.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 1,094
- Enrollment target
- 6
- Study locations
NCT06585241: Recruiting Phase 4 study of SARS-CoV-2, sponsored by ModernaTX.
NCT06585241 is a Phase 4 study of SARS-CoV-2 that is actively recruiting participants, run by ModernaTX. The registered enrollment target is 1,094 participants, below the 3,422-participant average among 34 other SARS-CoV-2 trials with a reported enrollment target (68% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06585241, a Phase 4 study of SARS-CoV-2, is actively recruiting participants, sponsored by ModernaTX.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 1,094 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to investigate the immunogenicity and safety of mRNA COVID-19 variant-containing vaccine formulations against the vaccine-matched variants and newly emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Conditions Studied
Interventions
- BIOLOGICAL mRNA-1273 Variant-containing Formulation
Study Locations (6)
Georgia
- CenExel - Atlanta
- CenExel - Decatur
Louisiana
- Velocity Clinical Research - Baton Rouge
Mississippi
- Velocity Clinical Research - Gulfport
Nebraska
- Velocity Clinical Research - Omaha
Virginia
- Richard Bennett - Clinical Research Partners - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,094 participants |
| Start Date | 2024-09-09 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
What NCT06585241 shows while recruiting
NCT06585241 is an interventional study that assigns participants to a tested intervention. Its 1,094 participants enrollment target places it among the larger protocols in the corpus, below the 3,422-participant average among 34 other SARS-CoV-2 trials with a reported enrollment target (68% lower).
The record links to 1 condition, with SARS-CoV-2 appearing as the primary indexed condition, and to 1 intervention - of which mRNA-1273 Variant-containing Formulation is the first listed.
NCT06585241 lists 6 locations in 5 states (Georgia, Louisiana, Mississippi).
Frequently Asked Questions
What is clinical trial NCT06585241 about?
NCT06585241 is a clinical study titled "A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations". The purpose of this study is to investigate the immunogenicity and safety of mRNA COVID-19 variant-containing vaccine formulations against the vaccine-matched variants and newly emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
What is the current status of trial NCT06585241?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 1,094 participants. The study started on 2024-09-09. Estimated completion is 2026-12-31.
What conditions does trial NCT06585241 study?
This clinical trial studies the following conditions: SARS-CoV-2.
What interventions are being tested in trial NCT06585241?
The interventions under investigation include: mRNA-1273 Variant-containing Formulation (BIOLOGICAL).
Who is sponsoring clinical trial NCT06585241?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06585241 being conducted?
This trial has 6 study locations across Georgia, Louisiana, Mississippi, Nebraska, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SARS-CoV-2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06585241's enrollment target sits among peer trials
1,094 9th of 34 higher than 26 of 34 other SARS-CoV-2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other SARS-CoV-2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
RECRUITING · Phase 4
-
Improving the Collaborative Health of Minority COVID-19 Survivor and Carepartner Dyads
RECRUITING · NA
-
Determinants of SARS (Severe Acute Respiratory Syndrome)-COV2 (COVID-19) Persistence After Convalescence
RECRUITING
-
Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease
RECRUITING · Phase 1
-
Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
ACTIVE NOT RECRUITING
-
COVID-19 Biorepository
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03754114 · 1,094 participants · NA
Brain Oxygen Optimization in Severe TBI, Phase 3
- NCT06118983 · 1,094 participants · NA
Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF)
- NCT06191744 · 1,095 participants · Phase 3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
- NCT07196722 · 1,092 participants · Phase 2
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI